Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy

This study has been completed.

Sponsor:

Information provided by:

Axcan Pharma

ClinicalTrials.gov Identifier:

NCT00669955

First received: April 29, 2008

Last updated: August 3, 2010

Last verified: August 2010

History of Changes

Results First Received: June 21, 2010

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Open Label; Primary Purpose: Treatment
Condition:	Helicobacter Infections
Interventions:	Drug: Omeprazole, amoxicillin, clarithromycin Drug: Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
First patient in: 11 June 2008 Last patient out: 22 June 2009 Patients were recruited from clinics and hospitals located in seven European Countries: Germany, Poland, Italy, France, Ireland, Spain, United Kingdom.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
If patient was on any contraindicated medications, such as H2 antagonists, sucralfate, or proton pump inhibitors, a washout period of 2 weeks began following informed consent signature, and patient returned to the clinic to perform the endoscopy and the C-13 urea breath test. Presence of H pylori needed to be confirmed by C-13 UBT and RUT at least.

Reporting Groups

	Description
Quadruple Therapy (OBMT) 10 Days	Omeprazole 20 mg BID (twice a day), and the 3 in 1 capsule, Pylera, containing Bismuth Subcitrate potassium 140 mg, metronidazole 125 mg and tetracycline 125 mg, administered as 3 capsules QID (four times day)
Triple Therapy (OAC) 7 Days	Ompeprazole 20 mg BID, Amoxicilin 500 mg 2 capsules BID and Clarithromycin 500 mg 1 tablet BID

Participant Flow: Overall Study

	Quadruple Therapy (OBMT) 10 Days	Triple Therapy (OAC) 7 Days
STARTED	218 ^[1]	222
COMPLETED	204	195
NOT COMPLETED	14	27
Adverse Event	3	5
Death	0	1
Withdrawal by Subject	2	3
Lost to Follow-up	5	7
Protocol Violation	2	7
Investigator Sponsor Jugement	0	1
not compliant with study drug/visit	2	3

[1]	216 patients received study drug. 2 patients were dispensed study drug but did not take it

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Quadruple Therapy (OBMT) 10 Days	Omeprazole 20 mg BID (twice a day), and the 3 in 1 capsule, Pylera, containing Bismuth Subcitrate potassium 140 mg, metronidazole 125 mg and tetracycline 125 mg, administered as 3 capsules QID (four times day)
Triple Therapy (OAC) 7 Days	Ompeprazole 20 mg BID, Amoxicilin 500 mg 2 capsules BID and Clarithromycin 500 mg 1 tablet BID
Total	Total of all reporting groups

Baseline Measures

	Quadruple Therapy (OBMT) 10 Days	Triple Therapy (OAC) 7 Days	Total
Number of Participants [units: participants]	218	222	440
Age [units: participants]
<=18 years	0	0	0
Between 18 and 65 years	184	194	378
>=65 years	34	28	62
Age [units: years] Mean ± Standard Deviation	48.53 ± 14.64	47.95 ± 14.52	48.24 ± 14.58
Gender [units: participants]
Female	105	100	205
Male	113	122	235
Region of Enrollment [units: participants]
Italy	10	10	20
Spain	7	6	13
France	15	17	32
Germany	92	91	183
Poland	91	93	184
United Kingdom	3	5	8

Outcome Measures

Show All Outcome Measures

1. Primary:

Helicobacter Pylori Eradication Confirmed by Urea Breath Test [ Time Frame: Week 6 and week 10 follow-up visits ]

Show Outcome Measure 1

2. Secondary:

Number of Patients Experiencing Treatment Emergent Adverse Events. [ Time Frame: at the end of treatment (day 8-14), week 6 and wek 10 follow-up visits. ]

Show Outcome Measure 2

3. Secondary:

H. Pylori Eradication and Presence or Past History of Peptic Ulcers [ Time Frame: Week 6 and week 10 follow-up visits ]

Show Outcome Measure 3

4. Secondary:

Clarithromycin Resistance [ Time Frame: Measured at baseline ]

Show Outcome Measure 4

5. Secondary:

Metronidazole Resistance [ Time Frame: Measured at baseline ]

Show Outcome Measure 5

6. Secondary:

Overall Compliance to Study Medications [ Time Frame: At the end of the treatment phase (days 8-14) ]

Show Outcome Measure 6

7. Secondary:

Number of Patients With Bismuth Plasma Concentrations Above the Toxic Level [ Time Frame: Baseline (both arms), end of treatment (Day 11-14) and end of study (Day 70) OBMT arm only ]

Show Outcome Measure 7

Serious Adverse Events

Hide Serious Adverse Events

Time Frame	Adverse events were recorded starting at the signing of the informed consent until the final visit (Day 70) or early withdrawal visit. Serious adverse events were followed until 30 days after the patient had stopped study participation.
Additional Description	Systematic assessment done for laboratory evaluations and bismuth plasma levels.

Reporting Groups

	Description
Quadruple Therapy (OBMT) 10 Days	Omeprazole 20 mg BID (twice a day), and the 3 in 1 capsule, Pylera, containing Bismuth Subcitrate potassium 140 mg, metronidazole 125 mg and tetracycline 125 mg, administered as 3 capsules QID (four times day)
Triple Therapy (OAC) 7 Days	Ompeprazole 20 mg BID, Amoxicilin 500 mg 2 capsules BID and Clarithromycin 500 mg 1 tablet BID

Serious Adverse Events

	Quadruple Therapy (OBMT) 10 Days	Triple Therapy (OAC) 7 Days
Total, serious adverse events
# participants affected / at risk	4/216 (1.85%)	3/222 (1.35%)
Cardiac disorders
Ventricular extrasystoles ^{* 1}
# participants affected / at risk	0/216 (0.00%)	1/222 (0.45%)
# events	0	1
Gastrointestinal disorders
Pancreatitis ^{* 1}
# participants affected / at risk	0/216 (0.00%)	1/222 (0.45%)
# events	0	1
Vomiting ^{* 1}
# participants affected / at risk	0/216 (0.00%)	1/222 (0.45%)
# events	0	1
General disorders
Condition aggravated ^{* 1}
# participants affected / at risk	0/216 (0.00%)	1/222 (0.45%)
# events	0	1
Pyrexia ^{* 1}
# participants affected / at risk	0/216 (0.00%)	1/222 (0.45%)
# events	0	1
Infections and infestations
Appendicitis ^{* 1}
# participants affected / at risk	0/216 (0.00%)	1/222 (0.45%)
# events	0	1
Proteus infection ^{* 1}
# participants affected / at risk	1/216 (0.46%)	0/222 (0.00%)
# events	1	0
e coli urinary tract infection ^{* 1}
# participants affected / at risk	1/216 (0.46%)	0/222 (0.00%)
# events	1	0
Metabolism and nutrition disorders
Dehydration ^{* 1}
# participants affected / at risk	0/216 (0.00%)	1/222 (0.45%)
# events	0	1
Malnutrition ^{* 1}
# participants affected / at risk	0/216 (0.00%)	1/222 (0.45%)
# events	0	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal carcinoma ^{* 1}
# participants affected / at risk	1/216 (0.46%)	0/222 (0.00%)
# events	1	0
Nervous system disorders
Vascular dementia ^{* 1}
# participants affected / at risk	0/216 (0.00%)	1/222 (0.45%)
# events	0	1
Psychiatric disorders
Schizophrenia ^{* 1}
# participants affected / at risk	1/216 (0.46%)	0/222 (0.00%)
# events	1	0
Renal and urinary disorders
Renal artery stenosis ^{* 1}
# participants affected / at risk	1/216 (0.46%)	0/222 (0.00%)
# events	1	0
Renal failure acute ^{* 1}
# participants affected / at risk	1/216 (0.46%)	0/222 (0.00%)
# events	1	0
Skin and subcutaneous tissue disorders
Eczema ^{* 1}
# participants affected / at risk	1/216 (0.46%)	0/222 (0.00%)
# events	1	0

*	Events were collected by non-systematic assessment
1	Term from vocabulary, PT

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: Restrictions vary in accordance with the agreement with investigators. Axcan will allow publication after a multi-centre publication or after an agreed period, subject to review by Axcan for confidentiality and intellectual protection.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Monique Giguere, PhD, Programs Director,
Organization: Axcan Pharma Inc.
phone: 1-800-565-3255 ext 2078

No publications provided by Axcan Pharma

Publications automatically indexed to this study:

Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F; Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011 Mar 12;377(9769):905-13. Epub 2011 Feb 21.

Responsible Party:	Dr. Monique Giguere, Axcan Pharma inc.
ClinicalTrials.gov Identifier:	NCT00669955 History of Changes
Other Study ID Numbers:	PYLHp07-01
Study First Received:	April 29, 2008
Results First Received:	June 21, 2010
Last Updated:	August 3, 2010
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices United Kingdom: National Health Service Spain: Ethics Committee Spain: Ministry of Health Poland: Ministry of Health Ireland: Irish Medicines Board Italy: National Bioethics Committee France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) Netherlands: Medicines Evaluation Board (MEB)

To Top